# Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871

> **NCT02971293** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 42 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease COPD

## Interventions

- **DRUG:** AZD8871 100 µg
- **DRUG:** AZD8871 600 µg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02971293
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-15
- **Primary completion:** 2017-08-18
- **Final completion:** 2017-08-18
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02971293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02971293, "Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02971293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*